Cold Spring Harbor Laboratory Joins the Illumina Genome Network
News May 28, 2012
Illumina, Inc. has announced that the Cold Spring Harbor Laboratory (CSHL) has joined the Illumina Genome Network (IGN) to provide researchers with broader access to whole genome sequencing (WGS) services.
IGN and CSHL will work in collaboration to bring together CSHL’s expertise in molecular biology and cancer genomics with Illumina’s industry-leading sequencing technology.
“We welcome the distinguished Cold Spring Harbor Laboratory to our prestigious group of IGN partners, and are excited to expand opportunities for deep scientific collaboration,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions Business.
Henry continued, “Through the Illumina Genome Network, we believe we can speed discovery in areas where CSHL excels, including approaches to understanding tumor development, progression and therapeutic response.”
“The goal of our work at the Cold Spring Harbor Laboratory is to apply our research on basic biological mechanisms to improve the diagnosis and treatment of cancer, as well as neurological disorders and other diseases,” said Richard McCombie, Professor, Cold Spring Harbor Laboratory.
McCombie continued, “By participating in IGN, we are enriching the capabilities of researchers as they strive to solve biology’s most challenging problems.”
IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data.
All IGN partners are experienced and well-published using Illumina TruSeq™ technology, and have completed Illumina’s Certified Service Provider (CSPro) certification.
Each possesses ten or more Illumina sequencing systems (HiSeq 2000 systems and/or Genome Analyzers), providing the scalability to handle large sequencing projects with rapid completion times.
CSHL joins six IGN partners who provide a full range of WGS services:
• The Broad Institute in Cambridge, Massachusetts
• British Columbia Cancer Agency in Vancouver, Canada
• University of Washington Department of Genome Sciences in Seattle, Washington
• National Center for Genome Resources in Santa Fe, New Mexico
• Macrogen & Genomic Medicine Institute in Seoul, Korea
• Illumina’s FastTrack Services lab in San Diego, California
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018